TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Acquired by Barclays PLC

Barclays PLC grew its position in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 341.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,067 shares of the company’s stock after purchasing an additional 44,903 shares during the period. Barclays PLC owned approximately 0.11% of TScan Therapeutics worth $289,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TCRX. Bank of New York Mellon Corp purchased a new stake in shares of TScan Therapeutics during the 2nd quarter valued at about $682,000. Rhumbline Advisers purchased a new stake in TScan Therapeutics during the 2nd quarter worth approximately $274,000. American Century Companies Inc. increased its holdings in TScan Therapeutics by 48.9% during the 2nd quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock worth $278,000 after purchasing an additional 15,596 shares during the last quarter. Cornercap Investment Counsel Inc. purchased a new stake in TScan Therapeutics during the 2nd quarter worth approximately $134,000. Finally, Brown Brothers Harriman & Co. purchased a new stake in TScan Therapeutics during the 2nd quarter worth approximately $445,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Trading Down 0.6 %

Shares of TCRX stock opened at $3.07 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics, Inc. has a 1 year low of $2.60 and a 1 year high of $9.69. The stock has a fifty day moving average of $4.12 and a two-hundred day moving average of $5.28. The firm has a market capitalization of $163.85 million, a PE ratio of -2.90 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.86 million. As a group, research analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Analyst Ratings Changes

TCRX has been the subject of several research reports. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a research report on Monday, December 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, December 11th.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.